アクセス数 : ?
ダウンロード数 : ?
ID 115654
著者
Kudo, Noriko National Center of Neurology and Psychiatry
Yamamori, Hidenaga National Center of Neurology and Psychiatry|Osaka University|Japan Community Health care Organization Osaka Hospital
Ishima, Tamaki Chiba University
Nemoto, Kiyotaka University of Tsukuba
Yasuda, Yuka National Center of Neurology and Psychiatry|Osaka University|Life Grow Brilliant Mental Clinic
Fujimoto, Michiko National Center of Neurology and Psychiatry|Osaka University
Azechi, Hirotsugu National Center of Neurology and Psychiatry
Niitsu, Tomihisa Chiba University
Ikeda, Manabu Osaka University
Iyo, Masaomi Chiba University
Fukunaga, Masaki National Institute for Physiological Sciences
Watanabe, Yoshiyuki Shiga University of Medical Science
Hashimoto, Kenji Chiba University
Hashimoto, Ryota National Center of Neurology and Psychiatry|Osaka University
キーワード
cognitive performance
matrix metalloproteinase-9
schizophrenia
Wechsler Adult Intelligence Scale
Wechsler Memory Scale
資料タイプ
学術雑誌論文
抄録
Aim: Matrix metalloproteinase‐9 (MMP‐9) has been shown to modulate synaptic plasticity and may contribute to the pathophysiology of schizophrenia. This study investigated the peripheral levels of MMP‐9 and its association with cognitive functions in patients with schizophrenia to see the possible involvement of MMP‐9 in pathophysiology of schizophrenia, especially in cognitive decline.
Methods: We measured the plasma levels of MMP‐9 in 257 healthy controls and 249 patients with schizophrenia, including antipsychotic drug–free patients. We also explored the possible association between plasma MMP‐9 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition (WAIS‐ III), the Wechsler Memory Scale‐Revised (WMS‐R), and the Rey Auditory Verbal Learning Test (AVLT).
Results: We found that the plasma levels of MMP‐9 were significantly higher in patients with schizophrenia, including antipsychotic drug–free patients, than in healthy controls. We found a significant negative association between plasma MMP‐9 levels and cognitive performance in controls and patients with schizophrenia.
Conclusion: Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased MMP‐9 levels are associated with cognitive impairment.
掲載誌名
Neuropsychopharmacology Reports
ISSN
2574173X
出版者
The Japanese Society of Neuropsychopharmacology|John Wiley & Sons
40
2
開始ページ
150
終了ページ
156
発行日
2020-02-05
権利情報
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系